- Home
- UPLD vs MAIA Comparison
UPLD vs MAIA Comparison
Compare UPLD & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPLD | MAIA |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 49.3M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | UPLD | MAIA |
|---|---|---|
| Price | $0.55 | $1.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.75 | N/A |
| AVG Volume (30 Days) | 266.9K | ★ 1.1M |
| Earning Date | 06-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.38 | 29.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,767,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.51 | $0.87 |
| 52 Week High | $3.90 | $3.19 |
Technical Indicators
Market Signals| Indicator | UPLD | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 13.20 | 39.61 |
| Support Level | N/A | $1.20 |
| Resistance Level | $1.62 | $1.66 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 8.53 | 17.13 |
Price Performance
Historical ComparisonAbout UPLD Upland Software Inc.
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.